Kevin Ling

Kevin Ling is a Senior Scientist at HotSpot Therapeutics, Inc. since May 2022, with prior experience as a Scientist II at FogPharma, where Kevin focused on advancing a direct β-catenin inhibitor. Previously, Kevin served as a Postdoctoral Research Fellow at Massachusetts Eye and Ear, developing methods to enhance gene editing efficiency through CRISPR technology. Kevin earned a PhD in Chemical and Biomolecular Engineering from the Georgia Institute of Technology, where research involved engineering protein nanoparticles for therapeutic applications. Earlier academic endeavors included independent research at Lafayette College and an NSF I-Corps initiative focused on the commercialization of a protein adjuvant for vaccines.